Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Not yet recruiting 1

Sponsor Class

UNKNOWN 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6Thoracic 3Head & Neck 3Breast 2Gynecologic 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 89Capecitabine 88Trastuzumab 81Docetaxel 81Paclitaxel 65Epirubicin 57pyrotinib 55Tamoxifen 54Letrozole 53Fulvestrant 49Vinorelbine 43Carboplatin 43Doxorubicin 41Radiotherapy 33Anastrozole 32exemestane 31Neoadjuvant Therapy 29palbociclib 27Drug Therapy 27Fluorouracil 24Bevacizumab 24pertuzumab 23Cisplatin 23eribulin 22Exercise 21130-nm albumin-bound paclitaxel 21Goserelin 20Gemcitabine 20Chemotherapy, Adjuvant 19Albumin-Bound Paclitaxel 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × lobaplatin × Breast × Clear all
NCT05546255 2022-09-19

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

ChineseAMS

Phase 2 Unknown
40 enrolled
Breast

Triple Negative Breast Neoplasms

NCT01483300 2012-01-24

Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast Cancer

Harbin Medical University

Phase 2 Unknown
80 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡